Todays notice of extraordinary shareholders meeting contains a proposal that the meeting resolve on extending the warrant program Series I & II 2014/17 by 12 months due to delay of development and completion of a product. The product referred to is Brighter One, which launch was aborted in February 2015.
For more information, please contact:
Truls Sjöstedt, CEO
Tel: +46 709 73 46 00
Henrik Norström, COO
Tel: +46 733 40 30 45
About Brighter AB (publ)
Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter's cloud-based service that continuously collects, analyzes and shares data on the user's terms.
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter's Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 - 454 32 50, CorporateFinance@remium.com,www.remium.com.
This information was distributed by Cision http://www.cisionwire.se/